Overview

Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)

Status:
Completed
Trial end date:
2020-10-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of soticlestat (TAK-935) on calculated 24-hour average pain intensity by the numeric pain scale (NPS).
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.